Where does ViaLase, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), ViaLase, Inc. ranks #16,493 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does ViaLase, Inc. hold?

ViaLase, Inc. holds 18 US utility patents granted between 2020 and 2025, spanning 4 technology areas.

What is ViaLase, Inc.'s Innovation Score?

ViaLase, Inc. has an Innovation Score of 49.0 out of 100 (top 15% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is ViaLase, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for ViaLase, Inc..

What does claim depth mean for ViaLase, Inc.'s patents?

ViaLase, Inc.'s patents average 22.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the ViaLase, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

ViaLase, Inc.

Q: What technology areas does ViaLase, Inc. focus on?

ViaLase, Inc.'s top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 18 patents, ranking #365 of 3,082 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 18 granted patents across 4 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Vialase ranks #16,493 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 4 technology areas.

#16,493
of 49,997 US assignees by volume: Top 15%
by Innovation Score (49.0/100): 22.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R16493 · US Corporation #16,493 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 18 grants
MID-PACK #16,493/49,997
PHOTO-FINISH Vatbox
CPC-NARROW A61F · 4 areas
INNOV-PAR 49.0/100
CLAIMS-DENSE 22.4 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Vatbox, Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Vialase’s 49.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.2 pts (21%) Velocity 18.3 pts (37%) Breadth 7.1 pts (14%) Claim depth 13.5 pts (27%)

Qualcomm Incorporated · highest

85
ViaLase · this assignee

49
3D Lighting… · lowest

7

What this shows Vialase's Innovation Score is 49.0/100 (top 15% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Vialase?

Each dot is one of Vialase’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Vialase’s own 22.4 claims/patent is ABOVE the 14.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Vialase vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Vialase's grants concentrate

ViaLase, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2023 (5 grants) versus a trough of 1 in 2022. By volume, Vialase sits between Volume Graphics GMBH and Vlaamse Instelling voor Technologisch Onderzoek NV (VITO).

Vialase's three-year grant acceleration

ViaLase, Inc. shows 11 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Volume Graphics

18
Vr-edu

18
Vatbox

18
Vedabio

18
Vidacare

18
Viking Range

18
Virco Mfg

18
Vlaamse Instellin…

18
Vialase ◀

18

What this shows ViaLase holds 18 patents at rank #16,497, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near ViaLase

By rank, the assignees closest to #16,497 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in ViaLase's primary technology class.

Vialase's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 15% higher than 85% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

ViaLase, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	11.1%
2021	2	11.1%
2022	1	5.6%
2023	5	27.8%
2024	5	27.8%
2025partial year	3	16.7%

Which technologies does ViaLase, Inc. patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 18

A61B - DIAGNOSIS; SURGERY; Identification 7

G02B - Optical Elements, Systems OR Apparatus 2

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

ViaLase, Inc.'s patent record in context - here's where to go next.

ViaLase, Inc.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 100% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #16,493 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare ViaLase, Inc. against Volume Graphics GMBH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 49.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.